Back to Results

A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety extension period up to 52 weeks, in children and adolescents with type 2 diabetes mellitus.

Study category: Diabetes & Hormone Disorders

Is this Study for You?

Let's Get Started!



Type of Study



Childrens Hospital Colorado

Principal Investigator
Petter Bjornstad,  MD

Petter Bjornstad, MD

Study ID

Protocol Number: 18-1223

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers